> NEWS RELEASES > ARCHIVE


Total records: 309 | Page: 1 of 62
[First page] [Previous page]   1  2 3 4 5   [Next page] [Last page]
Consultation response 18-Aug-08
Calpol 6+ Suspension Sugar Free in bottles – P to GSL – anomalous, unnecessary and unsafe, says NPA
The NPA believes that the reclassification of the bottle presentation of Calpol Six Plus from P to GSL could compromise patient safety, is anomalous in relation to other paracetamol products and is unnecessary as the product can be obtained in alternative packaging that carries less risk.

Consultation response 12-Aug-08
NPA concerned at wider release of prescribing data
The NPA has responded to the NHS’ Wider Release of Prescribing Data Consultation and expressed concern of the release of potential commercially sensitive data which could affect pharmacies neighbouring GP Surgeries.

Association 12-Aug-08
NPA takes members’ concerns to PPD
NPA staff visited the Prescription Pricing Division HQ in Newcastle to relay the continuing concerns of pharmacists about the PPD’s Capacity Improvement Programme (CIP).

Department of Health 12-Aug-08
Vascular Screening – NPA responds to DH Consultation
The NPA has responded to the Department of Health (DH) Consultation on economic modelling of vascular screening. The NPA is asking for the DH to review the contribution which community pharmacy can make as set out in the consultation document which is not in line with the DH recommendations in the Pharmacy White Paper ‘Pharmacy in England Building in Strengths – delivering the future April 2008.

Patient Choice 06-Aug-08
Reclassification of azithromycin from POM to P – an unparalleled opportunity
The NPA regards the switch of azithromycin from POM to P as an unparalleled opportunity for community pharmacy to become an alternative option for safe and effective treatment for chlamydia infection.